CHARACTERISTICS OF MAIN DRUG THERAPY TYPES IN SUBJECTS WITH ATRIAL FIBRILLATION IN POPULATION

Nowadays atrial fibrillation (AF) retains its leading position among arrhythmias in the world. Despite significant progress in treatment, this rhythm disturbance remains one of the leading causes of stroke (Str) and heart failure. Obviously, more action is needed on the ascertainment and the quality control of treatment of AF.

Aim. To assess the frequency and main groups of drug therapy in patients with AF in the Russian population sample of middle, elderly and senile age in cross-sectional study, 2015-2016.

Material and methods. The random urban population sample of men and women of 58-82 y.o. (n=2339) was examined in 2015-2016 in Novosibirsk. The entire subsample with AF included 76 people (3,2%). The presence of AF was defined by ECG with Minnesota coding. Cardiovascular diseases and their risk factors were assessed by standard epidemiological methods. We took into account the regular intake of drugs during the last two weeks, followed by coding with Anatomical therapeutic chemical classification system. ANOVA and nonparametric statistical methods were used.

Results. In studied entire subsample of subjects with AF aged 58-82 y.o., the average CHA2DS2VASc estimate of Str risk was of 4,7 in women and of 3,2 in men. Those with AF received beta-blockers (BB) in 43,4% of, angiotensin-converting-enzyme inhibitors (ACEi) — in 38,2%, cardiac glycosides — in 25,0%, anti-atherosclerotic drugs — about 33% and antidiabetic — 14,5%. Anticoagulants and antiplatelet were received in 42,1%, the aspirin was most frequent (25%), direct inhibitors of thrombin (NOAC) were received in 4% of subjects with AF. About 16% were in a drug-free state. Overall, the frequency of the medication taking of the drug treatment groups analyzed in the population sample was higher in women than in men.

Conclusion. In 2015-2016, the general spectrum of drug treatment in subjects with AF in Russian population sample aged 58-82 was in line with the recommended standards for AF treatment, but the coverage of treatment with main drug classes is insufficient (about 40%). The most common were BB, ACEi, lipid-lowering drugs, aspirin and digoxin. Every 4th subject with AF took an aspirin for the prevention of thromboembolism, and only 4% received NOAC.

1. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34: 2746-51. DOI: 10.1093/eurheartj/eht280.

2. Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014; 6: 213-20. DOI: 10.2147/CLEP.S47385.

3. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962. DOI: 10.1093/eurheartj/ehw210.

4. Sulimov VA, Yavelov IS, Panchenko EP, et al. Diagnosis and treatment of atrial fibrillation. Recommendations of RSC, VNOA, RACVS. Russian Journal of Cardiology 2013; 4, Suppl. 3: 1-100. (in Russ.) Сулимов В.А., Явелов И.С., Панченко Е.П. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА, АССХ. Российский кардиологический журнал 2013; 4, Приложение 3: 1-100.

5. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36: 1115-9. DOI: 10.1161/01.STR.0000166053.83476.4a.

6. Ott A, Breteler MM, de Bruyne MC, et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997; 28: 316-21. DOI: 10.1161/01.STR.28.2.316.

7. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920-5. DOI: 10.1161/01.CIR.0000072767.89944.6E.

8. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-64. DOI: 10.1016/S0002-9343(02)01236-6.

9. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. JACC 2007; 49: 986-92. DOI: 10.1016/j.jacc.2006.10.062.

10. Peasey A, Bobak M, Kubinova R, et al. Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: Rationale and design of the HAPIEE study. BMC Public Health 2006; 6: 255-65. DOI: 10.1186/1471-2458-6-255.

11. Rose GA, Blackburn H, Gillim RF, et al. Cardiovascular Survey Methods. 2th ed. Geneva: WHO, 1984. p. 223. ISBN: 9242400564.

12. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2017. Oslo, 2016. р. 291. [Internet] https://www.whocc.no/atc_ddd_index_and_guidelines/atc_ddd_index/ (21.04.2017).

13. Rehm J. Measuring quantity, frequency, and volume of drinking. Alcoholism: Clinical and Experimental Research. 1998; 2: 4-14. DOI: 10.1111/j.1530-0277.1998.tb04368.x.

14. Catapano AL, Graham I, Backer GD, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis 2016; 253:281-344. DOI: 10.1016/j.atherosclerosis.2016.08.018.

15. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34: 2159-219. DOI: 10.1093/eurheartj/eht151.

16. Shapkina MYu, Ryabikov AN, Voronina EV, et al. Atrial fibrillation: prevalence and crosssectional determinants in Novosibirsk population (HAPIEE cohort). Atherosclerosis 2016; 3: 22-7. (in Russ.) Шапкина М.Ю., Рябиков А.Н., Воронина Е.В. и др. Фибрилляция предсердий: распространенность и кросс-секционные детерминанты в популяции Новосибирска (когортa HAPIEE). Атеросклероз 2016; 3: 22-7.